ATF7IP2 (activating transcription factor 7 interacting protein 2) is a transcriptional coregulator that functions as a recruiter coupling transcription factors to the general transcription apparatus, thereby modulating transcriptional regulation and chr16 formation. ATF7IP2 forms hetero-trimeric complexes with SETDB1 and its paralog ATF7IP 1, where it prevents SETDB1 nuclear export by competing with Crm1 for binding to SETDB1 nuclear export signals. These complexes mediate MBD1-dependent transcriptional repression by recruiting histone-modifying activities that establish H3K9me3 marks and couple DNA methylation to heterochromatin formation 1. ATF7IP2 also functions as a distant enhancer-regulated gene controlled through chr16 interactions at the CLEC16A locus, where allele-specific transcription factor complexes mediate its expression and influence AKT signaling and CD4+ T cell immune responses 2. Regarding disease relevance, ATF7IP2 variants are associated with multiple human conditions: a GWAS meta-analysis identified ATF7IP2 (16p13.2-p13.13) as a susceptibility locus for endometrial cancer 3, a genome-wide association study of neuropathological features linked rs1097915 near GRIN2A/ATF7IP2 to lower parahippocampal Lewy body counts in Lewy body disease 4, variants correlated with visceral leishmaniasis relapse susceptibility 5, and ATF7IP2 emerged as an adverse prognostic factor in stage I lung squamous cell carcinoma 6. Additionally, rs28368872 near ATF7IP2 associated with AMD progression to choroidal neovascularization 7.